System Guide
Back to Search Results

Search Results

Display Options
Display Options
Select Fields
Export Results to CSV Create Report 0
+ Add all results to report

Report Produced: 04/03/2025 22:32 PM

Report Question ID Question Discussion Answer Year
20100032 First course treatment--Prostate: Is Degarelix coded as hormonal treatment for prostate cancer? Code the administration of Degarelix in the "Hormone Therapy" field. Assign code 01 [Hormone therapy administered as first course therapy]. This drug will be added to the next update of SEER*Rx. 2010
20010117 Grade, Differentiation--Prostate: Has SEER officially changed the conversion code for Gleason score 7 to poorly differentiated [grade 3]?

For cases diagnosed prior to 2003, there has been no change in SEER standards for converting a Gleason score to a grade. As described in the SEER Program Code Manual, Gleason score 7 is converted to moderately differentiated [grade 2]. ONLY if the pathology report lists moderately poorly differentiated IN ADDITION to the Gleason's score 7, would you code the case as 3.

For cases diagnosed in 2003 and later, please see question number 20031123.

 2001
20190002

Histology/Behavior--Brain and CNS: How should Histology and Behavior be coded for a polymorphous low-grade neuroepithelial tumor of the young (PLNTY) arising in the brain?

Assign code 9505/1 for ganglioglioma. Per our expert neuropathologist, according to the paper that has done the most work on PLNTY cases, it appears most closely related to the ganglioglioma. It is surely a neoplasm as it has recurrent mutations and fusions seen in other tumors, again, most like gangliogliomas.

 2019
20150045

MP/H/Histology--Thyroid:  What is the histology code for primary site of thyroid cancer with the histology of papillary thyroid carcinoma, classical and oncocytic type?

Code the histology to 8342/3, thyroid oncocytic (oxyphillic) papillary carcinoma.

2015
20190054

Update to current manual/Solid Tumor Rules (2018)/Histology--Brain and CNS: Table 6 (Non-Malignant CNS Equivalent Terms and Definitions) lists as a subtype/variant of craniopharyngioma 9350/1. This is not a valid histology per the ICD-O-3 or the 2018 ICD-O-3 Update Table. Is this actually supposed to read, ?

Adamantinomatous craniopharyngioma (9351/1) is a subtype of craniopharygioma. We will correct the Non-Malignant CNS Solid Tumor Rules in the next update.

 2019
20071037 CS Extension--Breast: Is the term "erosion" the same as "ulceration"?

This answer was provided in the context of CSv1 coding guidelines. The response may not be used after your registry database has been converted to CSv2.

"Erosion" is not synonymous with "ulceration" when coding CS extension for breast.

 2007
20020024 Reportability--Cervix: The SEER Program Code Manual lists CIN III and carcinoma in situ of the cervix as not being reportable for cases diagnosed in 1996 or later, but does not list "adenocarcinoma in situ" or "squamous cell carcinoma in situ." Are these histologies still reportable?

For primary site cervix uteri, only histologies with behavior codes of 3 [invasive] are reportable to SEER for all registries.

Some SEER registries have opted to continue to collect behavior codes of 2 [in situ] for cervix uteri primaries.

 2002
20210023

Reportability/Terminology--Head & Neck: Is an "evolving" squamous cell carcinoma of the vermillion border of the left lower lip reportable?

For solid tumors, ignore the term "evolving" and apply the registry rules for reportability to this case. Squamous cell carcinoma of the vermillion border of the lower lip (C001) is reportable.

 2021
20081009

Reportability/Diagnostic Confirmation: If a physician signs a case out as "precancerous melanosis of the face" (8741/2) and there is no microscopic confirmation of the disease, is this a reportable clinical diagnosis?

This case is reportable because the diagnosis of precancerous melanosis was stated by a recognized medical practitioner. Precancerous melanosis meets the reportable diagnosis criteria (See 2007 SEER Manual page 1).

Assign diagnostic confirmation code 8 [clinical diagnosis only].

Set the appropriate override flag for the SEER edit.

 2008
20031053 Reportability/History (Pre-2007)/Behavior Code--Ovary: Should the matrix principal in Rule F be applied to code a 2002 right ovary case to 8462/3 [Papillary serous borderline ovarian tumor] when peritoneal washings reveal the same histology?

For tumors diagnosed prior to 2007:

Do not apply the matrix principle in this case. This ovarian tumor is not reportable (behavior /1 per ICD-O-3). The peritoneal washings reveal the same histology (/1), rather than malignant cells. Based on the information provided, there is no evidence to support changing the behavior code.

For tumors diagnosed 2007 or later, refer to the MP/H rules. If there are still questions about how this type of tumor should be coded, submit a new question to SINQ and include the difficulties you are encountering in applying the MP/H rules.

 2003